1. Home
  2. Live Updates
  3. Parp inhibitor

Live Breaking News & Updates on Parp inhibitor

Stay informed with the latest breaking news from Parp inhibitor on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Parp inhibitor and stay connected to the pulse of your community

Dr DeBernardo on the Role of PARP Inhibitors in Frontline Ovarian Cancer

Robert DeBernardo, MD, discusses the current role of PARP inhibitors in the frontline treatment landscape in ovarian cancer.

Robert-debernardo , Lauraj-fogarty , Uterine-cancer-research , Department-of-gynecologic-oncology , Peritoneal-surface-malignancy-program , Gynecologic-oncology , Endowed-chair , Cleveland-clinic , Parp-inhibitor , Ovarian-cancer , Frontline ,

Dr Yadav Siddhartha: The Underutilization of BRCA Testing

Yadav Siddhartha, MD, discusses real-world data demonstrating the mass underutilization of BRCA testing in patients with breast cancer.

San-antonio , Texas , United-states , Yadav-siddhartha , Mayo-clinic , Brca , Brca-testing , Parp-inhibitor , Her2-negative , Metastatic-breast-cancer , Breast-cancer

PARP Inhibition Changes Individualized Treatment in Advanced Ovarian Cancer

The addition of PARP inhibitors for the treatment of patients with BRCA-mutated advanced ovarian cancer has provided clinicians with a stronger set of treatment options. Looking at how the BRCA mutation responds to these inhibitors is then vital to deciding the patient’s treatment path.

United-states , Texas , Louisiana , Chad , New-orleans , California , American , Dilip-solanki , Lars-neumann , Los-angeles , End-results-program , National-cancer-institute

Dr Rebecca Brooks Gives Expert Advice, Resources for Patients With or at High Risk of Ovarian Cancer

More ovarian cancer drug approvals and treatments have become available since 2014 than in the preceding 60 years combined, emphasized Rebecca Brooks, MD, UC Davis Health.

United-states , American , Foundation-for-women-cancer , Uc-davis-health , Rebecca-brooks , Image-credit , Ovarian-cancer-awareness-month , American-journal , Ovarian-cancer , Ovarian-cancer-awareness , Uc-davis

Adding Olaparib and Durvalumab Improved PFS in Patients Newly Diagnosed With Advanced Ovarian Cancer

Interim findings from the DUO-O trial could signal new options for women diagnosed with ovarian cancer at later stages who do not have a BRCA mutation.

United-states , Chicago , Illinois , American , Jennifer-markham , Astrazeneca , American-society-of-clinical-oncology , University-of-florida , American-society , Clinical-oncology , Annual-meeting , Merry-jennifer-markham

Future Outlook of Advanced Ovarian Cancer Treatment

Comprehensive insights on unmet needs, ongoing research, and the future of advanced ovarian cancer treatment.

Advanced-ovarian-cancer-treatment , Recent-updates , Later-line-maintenance-settings , Advanced-ovarian-cancer , Antibody-drug-conjugate , Soraya-trial , Mirvetuximab , Objective-response-rate , Overall-survival , Bevacizumab , Parp-inhibitor

Lynparza granted Priority Review in the US for BRCA-mutated HER2-negative high-risk early breast cancer

AstraZeneca’s supplemental New Drug Application (sNDA) for Lynparza (olaparib) has been accepted and granted Priority Review in the US for the adjuvant treatment of patients with BRCA-mutated (BRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery.

China , Japan , United-states , Cambridge , Cambridgeshire , United-kingdom , Kenilworth , Warwickshire , Canada , American , Daiichi-sankyo , Company-on-twitter

US singer Kelly Rowland boosts Co Antrim woman's cancer drug fundraising campaign


US singer Kelly Rowland boosts Co Antrim woman's cancer drug fundraising campaign
Julie Lillis (37), from Larne in Co Antrim, said she has been left "floored" by the generosity of people after £80,000 was raised for her within a week so she an access a promising new cancer drug which could help extend her life after she was diagnosed with triple negative breast cancer
Marie Louise McConville
30 June, 2021 01:00
US singer Kelly Rowland donated £28,000, on behalf of her sons, Titan and Noah, to a fundraising campaign for Co Antrim woman Julie Lillis, who is battling triple negative breast cancer and who needs to access a promising new drug, which is not yet available on the NHS. Picture by Ian West/PA Wire

Larne , United-kingdom , United-states , Northern-ireland , Craigavon , London , City-of , American , Tim-weatherspoon , Julie-lillis , Kelly-rowland , Noah-weatherspoon

Onxeo Receives Notice of Allowance for a New Patent Broadening the Protection of AsiDNA™ in combination with a PARP Inhibitor in the United States

Onxeo Receives Notice of Allowance for a New Patent Broadening the Protection of AsiDNA™ in combination with a PARP Inhibitor in the United States
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Parp-inhibitor , Uronext-paris , Omologous-recombination , Na-damage-response , Arp-inhibitors , Rca-mutation , Asdaq-copenhagen , Nxeo-sa- , He-company , Eadly-combination , Umor-cell

Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment wi


Font : A-A+
SALT LAKE CITY, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it received its first reimbursement decision for the Myriad myChoice
® Diagnostic System, which helps determine if women with ovarian cancer will benefit from the PARP inhibitor, Zejula
® (niraparib). myChoice was approved by Japan’s Ministry of Health, Labour and Welfare in September 2020 as a companion diagnostic for this indication and the reimbursement decision is now in effect. 
“Myriad’s myChoice test is the only one of its kind to be approved for reimbursement in Japan,” said Nicole Lambert, president of Myriad Genetic Laboratories. “This decision further advances precision medicine and helps ensure that more Japanese women have access to the most advanced therapies in their fight against ovarian cancer.”

Japan , Tokyo , United-states , Japanese , American , Jared-maxwell , Daisuke-aoki , Bracanalysis-cdx , Scott-gleason , Nicole-lambert , Hu-group-holdings-inc , Department-of-obstetrics